Search our extensive Laboratory Test Directory to find test codes, ordering recommendations, specimen stability information, Test Fact Sheets, and more.
Recommendations when to order or not order the test. May include related or preferred tests.
Use to monitor infliximab or infliximab biosimilar therapy.
New York DOH Approval Status
Indicates whether a test has been approved by the New York State Department of Health.
Testing is not New York state approved. Specimens from New York clients will be sent out to a New York state-approved laboratory.
Specimen Required
Patient PreparationInstructions patient must follow before/during specimen collection.
Collect specimen before next scheduled dose of infliximab or infliximab biosimilar (trough specimen). Avoid exposure to biotin (vitamin B7) for 12 hours prior to specimen collection.
CollectSpecimen type to collect. May include collection media, tubes, kits, etc.
Serum separator tube.
Specimen PreparationInstructions for specimen prep before/after collection and prior to transport.
Separate serum from cells ASAP. Transfer 1 mL serum to an ARUP standard transport tube. (Min 0.1 mL)
Storage/Transport TemperaturePreferred temperatures for storage prior to and during shipping to ARUP. See Stability for additional info.
Refrigerated.
Unacceptable ConditionsCommon conditions under which a specimen will be rejected.
Grossly hemolyzed, icteric, or lipemic specimens.
RemarksAdditional specimen collection, transport, or test submission information.
StabilityAcceptable times/temperatures for specimens. Times include storage and transport time to ARUP.
After separation from cells: Ambient: 2 days; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles).
Methodology
Process(es) used to perform the test.
Quantitative Electrochemiluminescence Immunoassay (ECLIA) with Acid Dissociation
Performed
Days of the week the test is performed.
Sun-Sat
Reported
Expected turnaround time for a result, beginning when ARUP has received the specimen.
3-7 days
Reference Interval
Normal range/expected value(s) for a specific disease state. May also include abnormal ranges.
Interpretive Data
May include disease information, patient result explanation, recommendations, or details of testing.
Infliximab Quantitation:
Limit of Quantitation = 0.5 ug/mL.
Results of 0.5 ug/mL or higher indicate the detection of infliximab or infliximab biosimilar. Therapeutic level may vary depending on the disease being treated.
Antibodies to Infliximab Quantitation:
Limit of Quantitation = 20 ng/mL.
Results of 20 ng/mL or higher indicate the detection of antibodies against infliximab or an infliximab biosimilar. Interpret in the context of infliximab or infliximab biosimilar trough concentration to determine clinical significance and impact on treatment efficacy.
The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
Other names that describe the test. Synonyms.
Avsola
Inflectra
Ixifi
Remicade
Renflexis
Infliximab and Antibodies to Infliximab Quantitation
Connect Sign In
